Potential biomarker of fracture risk and early osteoporosis; therapeutic target via S1PR modulation (e.g., S1PR3 agonists ↑ bone formation, S1PR2 antagonists ↓ resorption); potential in bone regeneration and treatment of Paget’s disease. Here, S1PR2 is linked to Paget disease.